Impact of somatic mutations on recurrence free survival (RFS) and overall survival (OS) for resected nonsmall cell lung cancer (NSCLC): results from the Japan Molecular Epidemiology for lung cancer study (JME).

被引：0
|
作者：
Tamiya, Akihiro
Koh, Yasuhiro
Kubo, Akihito
Ando, Masahiko
Isa, Shun-ichi
Saka, Hideo
Yoshimoto, Naoki
Serizawa, Masakuni
Takeo, Sadanori
Adachi, Hirofumi
Tagawa, Tsutomu
Kawashima, Osamu
Yamashita, Motohiro
Kataoka, Kazuhiko
Ichinose, Yukito
Takeuchi, Yukiyasu
Watanabe, Katsuya
Matsumura, Akihide
Kawaguchi, Tomoya
机构：
[1] Natl Hosp Org Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[2] Wakayama Med Univ, Wakayama, Japan
[3] Aichi Med Univ, Sch Med, Div Resp Med & Allergol, Nagakute, Aichi, Japan
[4] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan
[5] Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan
[6] Osaka City Univ, Grad Sch Med, Dept Clin Oncol, Osaka, Japan
[7] Shizuoka Canc Ctr Res Inst, Div Drug Discovery & Dev, Nagaizumi, Shizuoka, Japan
[8] Natl Hosp Org Kyushu Med Ctr, Fukuoka, Fukuoka, Japan
[9] Hokkaido Canc Ctr, Natl Hosp Org, Dept Thorac Surg, Sapporo, Hokkaido, Japan
[10] Natl Hosp Org Nagasaki Med Ctr, Omura, Japan
[11] Natl Hosp Org Shibukawa Med Ctr, Shibukawa, Japan
[12] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[13] Natl Hosp Org Iwakuni Clin Ctr, Iwakuni, Japan
[14] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Fukuoka, Japan
[15] Natl Hosp Org Toneyama Natl Hosp, Toyonaka, Osaka, Japan
[16] Natl Hosp Org Yokohama Med Ctr, Yokohama, Kanagawa, Japan
[17] Natl Hosp Org Kinki Chuo Chest Med Ctr, Osaka, Japan
[18] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8549
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8549
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Reply to the influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival An Analysis of the Survival, Epidemiology, and End Results Database
    Lally, Brian E.
    Hu, Jennifer J.
    Koniaris, Leonidas
    CANCER, 2013, 119 (06) : 1287 - 1288
  • [22] The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I-III resected NSCLC without known EGFR mutations.
    Gray, Jhanelle Elaine
    Salomonsen, Rachel
    Georgoulia, Nefeli
    Perez, Ignacio Diaz
    Wang, Alice
    Cai, Ling
    Wetherill, Graham
    Xiao, Yang
    Fielden, Claire
    Altorki, Nasser K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer - Impact on recurrence and survival
    Gu, CD
    Osaki, T
    Oyama, T
    Inoue, M
    Kodate, M
    Dobashi, K
    Oka, T
    Yasumoto, K
    ANNALS OF SURGERY, 2002, 235 (01) : 133 - 139
  • [25] MDM2 polymorphism and recurrence-free and overall survival in early stage non-small cell lung cancer (NSCLC).
    Heist, R. Suk
    Zhou, W.
    Cogan-Drew, T.
    Liu, G.
    Su, L.
    Neuberg, D.
    Lynch, T. J.
    Wain, J. C.
    Christiani, D. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 419S - 419S
  • [26] Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).
    Rutkowski, Jacek
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Treatment patterns, overall survival (OS), and disease-free survival (DFS) in early stage non-small cell lung cancer (NSCLC) following complete resection
    West, H.
    Hu, X.
    Burke, T.
    Walker, M. S.
    Wang, Y.
    Samkari, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S74 - S74
  • [28] Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC).
    Suk, R
    Park, S
    Liu, G
    Cogan-Drew, T
    Zhou, W
    Su, L
    Lynch, T
    Wain, J
    Christiani, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 842S - 842S
  • [29] Joint modeling of overall survival (OS) and tumor size for patient-level predictions of survival in non-small cell lung cancer (NSCLC)
    Onishchenko, Dmitry
    Dunyak, James
    Masson, Eric
    Helmlinger, Gabriel
    Peskov, Kirill
    Tomkinson, Helen
    Stanski, Donald
    Al-Huniti, Nidal
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S138 - S138
  • [30] Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice
    Martin Faehling
    Birgit Schwenk
    Sebastian Kramberg
    Sabine Fallscheer
    Matthias Leschke
    Jörn Sträter
    Robert Eckert
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 2059 - 2066
12345